SCM
RPRX icon

Suvretta Capital Management’s Royalty Pharma RPRX Stock Holding History

Suvretta Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,866,361
Closed -$52.8M – 110
2024
Q3 		$52.8M Hold
1,866,361
– – 1.69% 20
2024
Q2 		$49.2M Sell
1,866,361
-384,000
-17% -$10.6M 1.81% 18
2024
Q1 		$68.3M Sell
2,250,361
-1,637,341
-42% -$48.3M 2.54% 11
2023
Q4 		$109M Sell
3,887,702
-208,043
-5% -$5.72M 4.94% 3
2023
Q3 		$111M Buy
4,095,745
+1,048,696
+34% +$31.1M 6.01% 1
2023
Q2 		$93.7M Hold
3,047,049
– – 5.01% 1
2023
Q1 		$110M Buy
3,047,049
+1,072,424
+54% +$39.8M 4.64% 3
2022
Q4 		$78M Buy
1,974,625
+131,907
+7% +$5.51M 3.28% 9
2022
Q3 		$74M Sell
1,842,718
-1,235,788
-40% -$52.8M 3.07% 9
2022
Q2 		$129M Buy
3,078,506
+1,052,896
+52% +$43.2M 4.92% 1
2022
Q1 		$78.9M Buy
2,025,610
+58,337
+3% +$2.29M 2.41% 16
2021
Q4 		$78.4M Buy
1,967,273
+439,373
+29% +$17.1M 1.52% 25
2021
Q3 		$55.2M Buy
1,527,900
+798,523
+109% +$31M 0.93% 33
2021
Q2 		$29.9M Sell
729,377
-227,676
-24% -$9.68M 0.45% 50
2021
Q1 		$41.7M Sell
957,053
-2,599,880
-73% -$123M 0.62% 40
2020
Q4 		$178M Buy
3,556,933
+744,552
+26% +$31.6M 2.54% 15
2020
Q3 		$118M Buy
2,812,381
+659,381
+31% +$28.3M 2.13% 19
2020
Q2 		$105M Buy
+2,153,000
New +$107M 2.25% 16

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Suvretta Capital Management's RPRX Position: Q4 2024 in Review

Suvretta Capital Management sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 1,866,361 shares — an estimated $52.8M sold.

Suvretta Capital Management first reported a position in RPRX in Q2 2020 and held it in 18 quarters. The position peaked at $178M in Q4 2020. 416 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

  • Suvretta Capital Management reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
  • Suvretta Capital Management sold 1,866,361 Royalty Pharma shares in Q4 2024, an estimated $52.8M.
  • Suvretta Capital Management first reported a position in Royalty Pharma in Q2 2020 and held it in 18 quarters.
  • Suvretta Capital Management's Royalty Pharma position peaked at $178M in Q4 2020.
  • 416 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Suvretta Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.